We are excited to tell you that PrintoCent member, Finadvance, has secured a 1.2 million Euros seed funding round led by Finnish investor Athensmed!
– Finnadvance revolutionizes drug research and development – they’re the highest throughput platform for in-vitro blood-brain barrier. Now expanding into lung and gut fields.
– Their technology has practically limitless applications in fields such as biotech, chemical industry, safety and efficacy of nano/microparticles and biomaterials, and cosmetics evaluation – they can significantly speed up the preclinical R&D processes and save enormous spendings observed with conventional methods.
– Finnadvance has received EU, ELY and Business Finland funding to develop their R&D, and are now rapidly growing their team to commercialize their technology. Finnadvance currently has 17 team members, is 3 years old, and is already generating revenue.
More on Finnadvance news pages.
Printocent | VTT, Kaitoväylä 1, 90571 Oulu, Finland